Dr Reddy's launches high cholesterol drug in US market

The segment had US sales of approximately $74 million for 12 months ending Feb 2014

Hyderabad-based pharmaceuticals major, Dr Reddy's Laboratories Limited has launched fenofibrate capsules USP, indicated to treat high cholesterol and high triglyceride levels, in 43 mg and 130-mg strengths in the US market.

Dr Reddy's fenofibrate capsules USP, approved by the US FDA, is a therapeutic equivalent generic version of ANTARA capsules of Lupin Atlantis Holdings SA Corporation. The 43 mg capsules are available in bottle counts of 30 and 130 mg in bottle counts of 30 and 90, the company said in a filing to the BSE on Wednesday.

According to IMS Health's national sales perspective, the ANTARA capsules brand and generic had US sales of approximately $74 million for the 12 months ending February 2014.

 

Dr Reddy's scrip is currently trading at Rs 2,577.15 on the BSE, up 0.96%, over the previous close of Rs 2,552.70 a share.